“`html
Cost-Effectiveness of Sacituzumab Govitecan (SG) in the Treatment of Metastatic Triple-Negative Breast Cancer (mTNBC)
Background
- Sacituzumab govitecan (SG) has been approved in China for treating metastatic triple-negative breast cancer.
- SG improves survival compared to single-agent chemotherapy, but it is expensive.
- This study aimed to assess the cost-effectiveness of SG versus single-agent treatment from a Chinese healthcare perspective.
Methods
- Data was sourced from a clinical trial with 468 mTNBC patients.
- A model was used to compare long-term costs and effectiveness of SG versus single-agent treatment.
- Quality-adjusted life-months (QALMs) and costs were used to calculate the cost effectiveness ratio.
Results
- SG provided 5.17 additional QALMs at a cost of $44,792 per QALM, which is much higher than the threshold for cost-effectiveness in China.
- Sensitivity analysis showed that the price of SG was a key factor in its cost-effectiveness.
- Probability analysis indicated that SG was not cost-effective in the current setting.
- Scenario analyses confirmed the robustness of the results across different subgroups and time horizons.
- SG would need to reduce its price to about $2298 per month to have a 50% chance of being preferred over the current treatment.
Conclusions
- At the current price, SG is not cost-effective for treating mTNBC in China.
- A significant price reduction is necessary to improve its cost-effectiveness.
“`
